Exposure to Gestational Diabetes Mellitus (GDM) alters DNA methylation in placenta and fetal cord blood. (April 2021)

• Record Type: Journal Article
• Authors: Awamleh, Zain; Butcher, Darci T.; Hanley, Anthony; Retnakaran, Ravi; Haertle, Larissa; Haaf, Thomas; Hamilton, Jill; Weksberg, Rosanna
• Is Part Of: Diabetes research and clinical practice. Volume 174(2021)
• Publication Date: 2021-04
• Subjects: DNA methylation -- Epigenetics -- Fetal cord blood -- Gestational diabetes mellitus -- Metabolic programming -- Placenta; AHRR Aryl hydrocarbon receptor repressor -- CpG Cytosine- phosphate- Guanine -- DGDM Diet GDM -- DM Differential Methylation -- DNAm DNA Methylation -- DNMT DNA Methyltransferases -- EBF3 Early B cell transcription factor 3 -- FDR False Discovery Rate -- GDM Gestational Diabetes Mellitus -- IDF International Diabetes Federation -- IGDM Insulin GDM -- MHC Major Histocompatibility Complex -- NGT Normal Glucose Tolerance -- OGTT Oral Glucose Tolerance Test -- PPP1R3B Protein phosphatase 1 regulatory subunit 3B -- PRKCZ Protein kinase C zeta type -- PTPRN2 Protein Tyrosine Phosphatase Receptor Type N2; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2021.108690
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Background: Fetal exposure to maternal GDM increases offspring risk for adult-onset metabolic syndromes. Epigenetic modifications such as DNA methylation are modulators for fetal metabolic programming and susceptibility to adult-onset disease. This study investigates genome-wide DNA methylation in GDM exposed cord blood and placenta. Methods: Oral glucose tolerance testing between 24 and 28 weeks of pregnancy was used to determine severity of glucose intolerance. We measured DNA methylation (DNAm) using the Illumina Infinium 450 K array in 42 fetal cord blood and 36 placenta samples. Results: We identified 662 and 99 CpG sites in GDM placenta and cord blood, respectively at p -value <0.01 and a methylation difference >5% after adjustment for confounders. Annotated sites for AHRR and PTPRN2 were common to cord blood and placenta. Adding published GDM cord blood DNAm data we segregated patients based on treatment (Diet Only vs. +Insulin) and identified altered CpG sites to be unique to each GDM treatment group. Conclusion: Consistency in findings with other studies provides evidence for the role of DNAm in placental and fetal responses to hyperglycemia. However, segregating DNAm analysis of GDM samples based on treatment may help delineate whether observed DNAm alterations are reflective of adaptive responses or treatment effects in utero .